Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aimed at kidney disease shows promise in early trial

NCT ID NCT07096843

Disease control Sponsor: Climb Bio, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This phase 2 trial is testing a new drug, budoprutug (also known as TNT119), in 45 people with primary membranous nephropathy, a kidney disease that can lead to kidney failure. The study aims to see if the drug is safe and can help patients achieve remission. Participants receive the drug as an IV infusion on four separate days over about six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
budoprutug (TNT119)
What this could lead to
If successful, this could point toward a new treatment option for primary membranous nephropathy, potentially helping patients achieve remission and avoid long-term kidney damage.
What could go wrong
This is an early-phase, open-label trial with only 45 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of PMN with positive anti-PLA2R antibodies * CD19+ B cell count ≥40 cells/μL * UPCR ≥2.0 g/g * eGFR ≥35 mL/min/1.73 m² * Stable RAAS inhibitor therapy * Blood pressure \<150/90 mmHg at baseline * Adequate hematologic, hepatic, and renal function * Willing to use effective contraception (both sexes) * Other inclusion criteria may apply Exclusion Criteria: * Secondary Membranous Nephropathy * Rapidly progressive glomerulonephritis or other glomerulopathies * Prior B cell-depleting therapy within 24 weeks * Recent use of immunosuppressants * Active or high-risk infections * History of malignancy * Pregnancy or breastfeeding * Recent major surgery or hospitalization * Other exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary membranous nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary membranous nephropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    43 sites in 8 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Climb Bio Investigative Site #101

    RECRUITING

    Clifton Park, New York, 12065, United States

  • Climb Bio Investigative Site #104

    RECRUITING

    Sherman, Texas, 75092, United States

  • Climb Bio Investigative Site #105

    RECRUITING

    Orlando, Florida, 32086, United States

  • Climb Bio Investigative Site #106

    RECRUITING

    Indianapolis, Indiana, 46268, United States

  • Climb Bio Investigative Site #108

    RECRUITING

    Atlanta, Georgia, 30342, United States

  • Climb Bio Investigative Site #110

    RECRUITING

    Denver, Colorado, 80220, United States

  • Climb Bio Investigative Site #111

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • Climb Bio Investigative Site #204

    RECRUITING

    Taichung, 404, Taiwan

  • Climb Bio Investigative Site #205

    RECRUITING

    Taipei, 112, Taiwan

  • Climb Bio Investigative Site #401

    RECRUITING

    Beijing, Cheng District, 100034, China

  • Climb Bio Investigative Site #402

    RECRUITING

    Wuxi, Jiangsu, 214023, China

  • Climb Bio Investigative Site #403

    NOT_YET_RECRUITING

    Beijing, Changping District, 102218, China

  • Climb Bio Investigative Site #404

    NOT_YET_RECRUITING

    Yibin, Sichuan, 644000, China

  • Climb Bio Investigative Site #405

    NOT_YET_RECRUITING

    Jinan, Shandong, 250014, China

  • Climb Bio Investigative Site #406

    NOT_YET_RECRUITING

    Beijing, Xicheng District, 100044, China

  • Climb Bio Investigative Site #407

    NOT_YET_RECRUITING

    Xi'an, Shaanxi, 710061, China

  • Climb Bio Investigative Site #408

    NOT_YET_RECRUITING

    Shenzhen, Guangdong, 518036, China

  • Climb Bio Investigative Site #409

    NOT_YET_RECRUITING

    Yantai, Shandong, 264000, China

  • Climb Bio Investigative Site #501

    RECRUITING

    Porto Alegre, 90020-090, Brazil

  • Climb Bio Investigative Site #502

    RECRUITING

    Belo Horizonte, 30150-320, Brazil

  • Climb Bio Investigative Site #503

    RECRUITING

    São Paulo, 05403-000, Brazil

  • Climb Bio Investigative Site #504

    RECRUITING

    São Paulo, 05403-000, Brazil

  • Climb Bio Investigative Site #505

    RECRUITING

    Minas Gerais, 36010-570, Brazil

  • Climb Bio Investigative Site #506

    RECRUITING

    Pernambuco, 50670-901, Brazil

  • Climb Bio Investigative Site #601

    RECRUITING

    CABA, C1111, Argentina

  • Climb Bio Investigative Site #604

    RECRUITING

    CABA, C1425, Argentina

  • Climb Bio Investigative Site #606

    RECRUITING

    Santa Fe, S3000, Argentina

  • Climb Bio Investigative Site #701

    NOT_YET_RECRUITING

    Temuco, Araucania, 4811230, Chile

  • Climb Bio Investigative Site #702

    NOT_YET_RECRUITING

    Santiago, Santiago Metropolitan, 8320165, Chile

  • Climb Bio Investigative Site #703

    NOT_YET_RECRUITING

    Valdivia, Los Ríos Region, 5020000, Chile

  • Climb Bio Investigative Site #802

    RECRUITING

    Ternopil, 46002, Ukraine

  • Climb Bio Investigative Site #803

    RECRUITING

    Ivano-Frankivsk, 76008, Ukraine

  • Climb Bio Investigative Site #804

    RECRUITING

    Rivne, 33027, Ukraine

  • Climb Bio Investigative Site #805

    RECRUITING

    Kyiv, 03151, Ukraine

  • Climb Bio Investigative Site #901

    RECRUITING

    Tbilisi, 0144, Georgia

  • Climb Bio Investigative Site #902

    RECRUITING

    Tbilisi, 0114, Georgia

  • Climb Bio Investigative Site #903

    RECRUITING

    Tbilisi, 0112, Georgia

  • Climb Bio Investigative Site# 201

    RECRUITING

    Taipei, 110, Taiwan

  • Climb Bio Investigative Site# 202

    RECRUITING

    Taipei, 100, Taiwan

  • Climb Bio Investigative Site# 203

    RECRUITING

    Taipei, 235, Taiwan

  • Climb Bio Investigative Site# 602

    RECRUITING

    Buenos Aires, B1629, Argentina

  • Climb Bio Investigative Site# 603

    RECRUITING

    Buenos Aires, B1888, Argentina

  • Climb Bio Investigative Site# 801

    RECRUITING

    Kyiv, 02125, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.